🏛️ Verified NIH Record • Updated 2026-04-30

meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis (NCT05715814)

A Single Arm, Open Label, Pilot Study to Evaluate the Safety and Efficacy of Once Daily 25mg Empagliflozin in Patients on Peritoneal Dialysis With Residual Kidney Function

🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: University Health Network, Toronto

🩺 Plain-English Summary (8th-Grade Level)

The primary aim of this study is to determine the safety and mechanisms of SGLT2 inhibition in individuals on peritoneal dialysis (PD) with residual kidney function (RKF).

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (4 items) and avoid the listed exclusions (15 items).

Location: Toronto General Hospital — Toronto, Ontario

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • Type 1 diabetes.
  • Recent (in the 30 days prior to screening) acute coronary syndrome or cerebrovascular event.
  • PD peritonitis within 30 days of screening.
  • History of organ transplant, including pancreas, pancreatic islet cells or kidney transplant.
  • Planned surgery/procedures or radiologic investigations requiring contrast during the trial.
  • Pregnant, planning to become pregnant, or nursing an infant during the study period
  • History of any DKA event
  • Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells (e.g., malaria, babesiosis, hemolytic anemia) at screening.
  • Women who are pregnant, nursing, or who plan to become pregnant whilst in the trial.
  • Alcohol or drug abuse within the 3 months prior to screening that would interfere with trial participation based on Investigator's judgement.
  • Use of SGLT2 inhibitor within 30 days prior to screening.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

  • Toronto General Hospital — Toronto, Ontario

📞 Contact the Study Coordinator

Phone: (416) 340-4800

Email: vesta.lai@uhn.ca

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All Peritoneal Dialysis Complication clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗